Futura Medical (GB:FUM) has released an update.
Futura Medical PLC, specializing in the development of sexual health products, has announced updated revenue expectations of £13.4 million for 2024 and £18.6 million for 2025, as detailed in a Trinity Delta analyst report. The company’s flagship product, Eroxon®, the only over-the-counter topical gel for erectile dysfunction, is gaining recognition in the market with several industry awards and global distribution partnerships.
For further insights into GB:FUM stock, check out TipRanks’ Stock Analysis page.
